title: Heart-type fatty acid binding protein as a marker of reperfusion after thrombolytic therapy.
abstract: Accurate, rapid, and simple noninvasive measures of infarct-related artery (IRA) patency are needed to identify patients with failed coronary reperfusion for rescue percutaneous coronary intervention (PCI). Heart-type Fatty Acid Binding Protein (H-FABP) is a small, cytosolic protein found in high concentrations in the myocardium. We evaluated the efficacy of H-FABP as a marker for successful reperfusion after thrombolysis. Fifty-eight subjects from the TIMI 14 trial had H-FABP and myoglobin concentrations measured at baseline (immediately prior to thrombolysis) and 60, 90, and 180 min after thrombolysis. All patients underwent coronary angiography at 90 min. By 60 min after thrombolysis, median concentrations of H-FABP and myoglobin were significantly higher in patients with a patent IRA than in those with an occluded IRA (P<0.01 for each). Similarly, the 60 and 90 min/baseline H-FABP and myoglobin ratios were significantly higher among patients with a patent IRA (P<0.01 for each). There were no significant differences in marker concentrations or ratios between patients with TIMI grade 2 and TIMI grade 3 flow. The area under the ROC curve tended to be greater for the 60 and 90 min/baseline myoglobin ratios than for similar ratios of H-FABP (0.71 and 0.73 vs. 0.64 and 0.62; P=ns). In conclusion, successful reperfusion can be detected within the first 60 min after thrombolysis with either H-FABP or myoglobin. Despite a favorable kinetic profile, however, H-FABP does not appear to represent a significant advance over myoglobin in the noninvasive detection of reperfusion after thrombolysis.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. jdelemos@rics.bwh.harvard.edu
authors.forename: J A
authors.initials: JA
authors.lastname: de Lemos
authors.forename: E M
authors.initials: EM
authors.lastname: Antman
authors.forename: D A
authors.initials: DA
authors.lastname: Morrow
authors.forename: J
authors.initials: J
authors.lastname: Llevadot
authors.forename: R P
authors.initials: RP
authors.lastname: Giugliano
authors.forename: S A
authors.initials: SA
authors.lastname: Coulter
authors.forename: K C
authors.initials: KC
authors.lastname: Schuhwerk
authors.forename: S
authors.initials: S
authors.lastname: Arslanian
authors.forename: C H
authors.initials: CH
authors.lastname: McCabe
authors.forename: C M
authors.initials: CM
authors.lastname: Gibson
authors.forename: N
authors.initials: N
authors.lastname: Rifai
mesh_terms: D015415:Biomarkers / Q000097:blood*; D002352:Carrier Proteins / Q000097:blood*; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000503:physiopathology; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D006801:Humans; D018996:Myelin P2 Protein / Q000097:blood*; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D015425:Myocardial Reperfusion; D009206:Myocardium / Q000737:chemistry; D009211:Myoglobin / Q000097:blood; D009363:Neoplasm Proteins; D015912:Thrombolytic Therapy; D025521:Tumor Suppressor Proteins; D014654:Vascular Patency
chemical_list: D015415:Biomarkers; D002352:Carrier Proteins; C107608:FABP7 protein, human; D000071438:Fatty Acid-Binding Protein 7; D050556:Fatty Acid-Binding Proteins; D018996:Myelin P2 Protein; D009211:Myoglobin; D009363:Neoplasm Proteins; D025521:Tumor Suppressor Proteins